These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
489 related articles for article (PubMed ID: 33991294)
21. Antisense oligonucleotides on neurobehavior, respiratory, and cardiovascular function, and hERG channel current studies. Kim TW; Kim KS; Seo JW; Park SY; Henry SP J Pharmacol Toxicol Methods; 2014; 69(1):49-60. PubMed ID: 24211663 [TBL] [Abstract][Full Text] [Related]
22. Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Hua Y; Sahashi K; Hung G; Rigo F; Passini MA; Bennett CF; Krainer AR Genes Dev; 2010 Aug; 24(15):1634-44. PubMed ID: 20624852 [TBL] [Abstract][Full Text] [Related]
23. Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for Miller T; Cudkowicz M; Shaw PJ; Andersen PM; Atassi N; Bucelli RC; Genge A; Glass J; Ladha S; Ludolph AL; Maragakis NJ; McDermott CJ; Pestronk A; Ravits J; Salachas F; Trudell R; Van Damme P; Zinman L; Bennett CF; Lane R; Sandrock A; Runz H; Graham D; Houshyar H; McCampbell A; Nestorov I; Chang I; McNeill M; Fanning L; Fradette S; Ferguson TA N Engl J Med; 2020 Jul; 383(2):109-119. PubMed ID: 32640130 [TBL] [Abstract][Full Text] [Related]
25. Antisense oligonucleotides: absorption, distribution, metabolism, and excretion. Shadid M; Badawi M; Abulrob A Expert Opin Drug Metab Toxicol; 2021 Nov; 17(11):1281-1292. PubMed ID: 34643122 [TBL] [Abstract][Full Text] [Related]
26. Intrathecal Delivery of Therapeutic Oligonucleotides for Potent Modulation of Gene Expression in the Central Nervous System. Kennedy Z; Gilbert JW; Godinho BMDC Methods Mol Biol; 2022; 2434():345-353. PubMed ID: 35213030 [TBL] [Abstract][Full Text] [Related]
27. Direct intraventricular delivery of drugs to the rodent central nervous system. DeVos SL; Miller TM J Vis Exp; 2013 May; (75):e50326. PubMed ID: 23712122 [TBL] [Abstract][Full Text] [Related]
29. Non-invasive Imaging of Antisense Oligonucleotides in the Brain via In Vivo Click Chemistry. Cook BE; Archbold J; Nasr K; Girmay S; Goldstein SI; Li P; Dandapani S; Genung NE; Tang SP; McClusky S; Plisson C; Afetian ME; Dwyer CA; Fazio M; Drury WJ; Rigo F; Martarello L; Kaliszczak M Mol Imaging Biol; 2022 Dec; 24(6):940-949. PubMed ID: 35655109 [TBL] [Abstract][Full Text] [Related]
30. Routine Cerebrospinal Fluid (CSF) Parameters in Patients With Spinal Muscular Atrophy (SMA) Treated With Nusinersen. Wurster CD; Koch JC; Cordts I; Dreyhaupt J; Otto M; Uzelac Z; Witzel S; Winter B; Kocak T; Schocke M; Weydt P; Wollinsky K; Ludolph AC; Deschauer M; Lingor P; Tumani H; Hermann A; Günther R Front Neurol; 2019; 10():1179. PubMed ID: 31787927 [No Abstract] [Full Text] [Related]
31. Macrophage inclusions in cerebrospinal fluid following treatment initiation with antisense oligonucleotide therapies in motor neuron diseases. Vidovic M; Menschikowski M; Freigang M; Lapp HS; Günther R Neurol Res Pract; 2024 Feb; 6(1):11. PubMed ID: 38383503 [TBL] [Abstract][Full Text] [Related]
32. Spinal muscular atrophy: antisense oligonucleotide therapy opens the door to an integrated therapeutic landscape. Wood MJA; Talbot K; Bowerman M Hum Mol Genet; 2017 Oct; 26(R2):R151-R159. PubMed ID: 28977438 [TBL] [Abstract][Full Text] [Related]
34. Antisense Drugs Make Sense for Neurological Diseases. Bennett CF; Kordasiewicz HB; Cleveland DW Annu Rev Pharmacol Toxicol; 2021 Jan; 61():831-852. PubMed ID: 33035446 [TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetic-pharmacodynamic modeling for reduction of hepatic apolipoprotein B mRNA and plasma total cholesterol after administration of antisense oligonucleotide in mice. Shimizu R; Kitade M; Kobayashi T; Hori S; Watanabe A J Pharmacokinet Pharmacodyn; 2015 Feb; 42(1):67-77. PubMed ID: 25376372 [TBL] [Abstract][Full Text] [Related]
36. Spinal distribution and metabolism of 2'-O-(2-methoxyethyl)-modified oligonucleotides after intrathecal administration in rats. Butler M; Hayes CS; Chappell A; Murray SF; Yaksh TL; Hua XY Neuroscience; 2005; 131(3):705-15. PubMed ID: 15730875 [TBL] [Abstract][Full Text] [Related]
39. Systemic, postsymptomatic antisense oligonucleotide rescues motor unit maturation delay in a new mouse model for type II/III spinal muscular atrophy. Bogdanik LP; Osborne MA; Davis C; Martin WP; Austin A; Rigo F; Bennett CF; Lutz CM Proc Natl Acad Sci U S A; 2015 Oct; 112(43):E5863-72. PubMed ID: 26460027 [TBL] [Abstract][Full Text] [Related]
40. Intrathecal administration of antisense oligonucleotide against p38α but not p38β MAP kinase isoform reduces neuropathic and postoperative pain and TLR4-induced pain in male mice. Luo X; Fitzsimmons B; Mohan A; Zhang L; Terrando N; Kordasiewicz H; Ji RR Brain Behav Immun; 2018 Aug; 72():34-44. PubMed ID: 29128611 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]